A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 17,099 shares of ITCI stock, worth $1.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
17,099
Holding current value
$1.43 Million
% of portfolio
0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$67.99 - $80.84 $1.16 Million - $1.38 Million
17,099 New
17,099 $1.25 Million
Q3 2023

Nov 13, 2023

SELL
$52.09 - $64.1 $559,134 - $688,049
-10,734 Reduced 29.09%
26,161 $1.36 Million
Q2 2023

Aug 10, 2023

BUY
$54.67 - $66.44 $62,269 - $75,675
1,139 Added 3.19%
36,895 $2.34 Million
Q1 2023

May 09, 2023

BUY
$43.8 - $56.99 $795,364 - $1.03 Million
18,159 Added 103.19%
35,756 $1.94 Million
Q4 2022

Feb 10, 2023

BUY
$44.07 - $54.45 $289,628 - $357,845
6,572 Added 59.61%
17,597 $931,000
Q3 2022

Nov 10, 2022

BUY
$42.7 - $59.99 $32,964 - $46,312
772 Added 7.53%
11,025 $513,000
Q2 2022

Aug 05, 2022

BUY
$43.0 - $65.64 $440,879 - $673,006
10,253 New
10,253 $585,000
Q4 2019

Feb 12, 2020

SELL
$7.26 - $38.49 $192,796 - $1.02 Million
-26,556 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$7.47 - $14.03 $198,373 - $372,580
26,556 New
26,556 $198,000
Q1 2018

May 14, 2018

SELL
$15.16 - $25.49 $173,203 - $291,223
-11,425 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$14.27 - $16.79 $163,034 - $191,825
11,425
11,425 $165,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.9B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.